





























- Reverses it by Down-Regulating Nrf2-Mediated Cellular Defense Response. *Mol Carcinog* 2013;52:824-34.
65. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. *Free Radic Biol Med* 2008;45:537-46.
  66. Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. *Cancer Res* 2004;64:3148-54.
  67. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. *Proc Natl Acad Sci U S A* 2001;98:3410-5.
  68. Rutz HP, Herr I. Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. *Cancer Biol Ther* 2004;3:715-8.
  69. Cook AM, McDonnell AM, Lake RA, Nowak AK. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. *Oncoimmunology* 2016;5:e1066062.
  70. Stahn C, Buttgerit F. Genomic and nongenomic effects of glucocorticoids. *Nat Clin Pract Rheumatol* 2008;4:525-33.
  71. Namani A, Li YL, Wang XJ, Tang XW. Modulation of NRF2 signaling pathway by nuclear receptors: Implications for cancer. *Biochim Biophys Acta* 2014;1843:1875-85.
  72. Damia G, Broggin M. Platinum Resistance in Ovarian Cancer: Role of DNA Repair. *Cancers* 2019;11:119.
  73. Flaherty RL, Owen M, Fagan-Murphy A, Intabli H, Healy D, et al. Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer. *Breast Cancer Res* 2017;19:35.
  74. Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, et al. beta-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8(+) T Cells and Undermines Checkpoint Inhibitor Therapy. *Cancer Res* 2017; 77:5639-51.
  75. Nissen MD, Sloan EK, Mattarollo SR. beta-Adrenergic Signaling Impairs Antitumor CD8(+) T-cell Responses to B-cell Lymphoma Immunotherapy. *Cancer Immunol Res* 2018;6:98-109.
  76. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. *Pigment Cell Melanoma Res* 2015;28:245-53.